XVIVO: TransMedics US OCS Heart launch continues in Q2 - Redeye

XVIVO’s peer and future competitor TransMedics continues to open up the US Heart transplant market with its OCS Heart Perfusion System. The company records 156% of growth in Q2 and increases the guide for the full year. This is good news ahead of XVIVO’s future launch of its cold oxygenated perfusion solution in Australia, New Zeeland, Europe and the US.

Länk till analysen i sin helhet: https://www.redeye.se/research/927587/xvivo-transmedics-us-ocs-heart-launch-continues-in-q2?utm_source=finwire&utm_medium=RSS